Press Releases

CALIXAR appears in many different kinds of news where we display our expertise and technology throughout the world.

December 16, 2021

Calixar member of the 2021 “R&D Booster” program is working in close collaboration with its partners (Biotem and the CNRS/Université Claude Bernard Lyon 1) on the IMABGEN Platform project.

April 12, 2021

Calixar invests €1 million in pipeline of highly druggable membrane protein targets and native antigens.

April 27, 2020

CALIXAR enters into collaboration with Kobe University to explore stabilized native membrane protein dynamics in reconstituted membranes using fluorescence.

March 10, 2020

Calixar launches new funding round to establish business strategy.

February 13, 2020

CALIXAR enters into Cryo-EM collaboration with CBI/IGBMC to unlock structure-based drug design for challenging membrane protein targets.

November 6, 2019

CALIXAR and COSMO BIO to conclude distribution agreement.

May 20, 2019

Biotem enters into collaboration with Calixar for the development of therapeutic antibodies against membrane protein targets.

April 29, 2019

Calixar signs exclusive licensing agreement with Regeneron on undisclosed therapeutic target.

April 5, 2019

Calixar announces a collaborative research agreement with Thermo Fisher Scientific on multiple membrane proteins of high relevance to drug discovery.

November 28, 2017

CALIXAR and ASTRAZENECA to publish new insight on KCC2 architecture and function in Scientific Reports.

June 24, 2016

CALIXAR and University of Avignon to launch new research lab developing innovative chemistry for target discovery.

December 4, 2015

CALIXAR and Biouniversa to publish unprecedented new insights on Pancreatic Ductal Adenocarcinoma (PDAC) in Nature Communications.

February 23, 2015

CALIXAR raises €1 Million.

October 20, 2014

CALIXAR and ASTON University collaboration on multidrug resistance targets.

September 23, 2014

Major Breakthrough in Influenza Vaccines.

June 16, 2014

New strategic compounds: CALIXAR to extend its portfolio of strategic compounds for complex pharmaceutical target isolation.

October 1, 2013

ABL Strategic Marketing.

June 18, 2012

CALIXAR closes an initial €875,000 funding round.